Clinical Trial Update: The Safety and Effectiveness of BI-RG-587 in HIV-Infected Patients [Phase 1]

View source ↗

Summary

This Phase 1 trial assessed the safety and preliminary effectiveness of BI-RG-587 in HIV-infected patients and has completed the study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• BI-RG-587

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1 | Status: COMPLETED